Pharmaceuticals & Biotechnology
GSK is a global biopharmaceutical company focused on vaccines and specialty medicines. Its research priorities include respiratory and immunology, oncology, HIV and infectious diseases, alongside a portfolio of established general medicines.
Research, clinical development, manufacture and sale of vaccines, specialty medicines, HIV therapies and general prescription medicines, supported by a large global R&D pipeline.
Global healthcare markets, with the United States and Europe particularly important alongside substantial international vaccine and medicines businesses.
New drug and vaccine launches, clinical-trial results, regulatory approvals, uptake of specialty medicines, HIV franchise growth, vaccine demand, patent life and delivery of the Accelerate Growth pipeline.
Clinical failures, regulatory setbacks, patent expiries, pricing pressure, litigation, vaccine-demand fluctuations, competition and the high cost and uncertainty of pharmaceutical R&D.
28 July 2026: GSK released second-quarter results alongside its Accelerate Growth investor event, focusing attention on the specialty-medicines and vaccines pipeline and the portfolio intended to support growth through the end of the decade.
Pays quarterly. The Q4 2025 dividend of 18p went ex-dividend on 19 February 2026 and the Q1 2026 dividend of 17p went ex-dividend on 14 May and was paid on 9 July. The Q2 dividend went ex-dividend on 13 August and is payable on 8 October.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.